Chemotherapy
IND filed for phase I/II trial of MagneTarg system to deliver mitomycin C
Published in Medical Devices and Surgical Technology Week, February 8th, 2004
FeRx, Inc., a targeted drug delivery company, announced that the U.S. Food and Drug Administration has allowed the phase I/II clinical trial submitted in an investigational new drug (IND) application using the company's proprietary MagneTarg drug-delivery system to deliver magnetic targeted carriers (MTCs) combined with the chemotherapeutic agent mitomycin C (MTC-MMC) to patients with non-small cell lung cancer (NSCLC) via intra-arterial administration.
The proposed study is a phase I/II escalating, single-dose, cohort trial in up to 50 patients with symptomatic advanced NSCLC and who are no longer responsive to conventional treatment. These patients will receive a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
More Articles from Medical Devices and Surgical Technology Week
- Arteriosclerosis
Device perfects tissue-generated blood vessels - Back Pain
EpiCept provides update on two deals made in 2003 - Menopause
Quantitative ultrasound identifies women at risk for osteoporotic fracture - Mergers and Acquisitions
Acquisition of Invivo Corp. clears regulatory review waiting period - Mergers and Acquisitions
Henry Schein acquires European dental distributors - Mergers and Acquisitions
Medical device contract research business acquired - More from this issue of Medical Devices and Surgical Technology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
